US$ 29.02
fda bpc-157 unapproved drug warning letter new The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned FDA Sends Warning Letters to
Description
Food and Drug Administration has classified BPC-157, GHK-Cu (for injectable routes of administration), and TB-500 (Thymosin 4 fragment) as Category 2 Bulk Drug Substancessubstances with safety concerns that are prohibited from being compounded by licensed pharmacies for human use

Review the documented purity and identity/composition data for this batch
Abud Bakri GHKCU is a tripeptide with a copper ion in the middle
NAD+ levels naturally decline with age, leading to decreased energy, cognitive function, and overall vitality
Neither compound has completed the FDA approval process
